Tran, Hien Thi
Wan, Murphy Lam Yim
Ambite, Ines
Cavalera, Michele
Grossi, Mario
Háček, Jaromir
Esmaeili, Parisa
Carneiro, António N. B. M.
Chaudhuri, Arunima
Ahmadi, Shahram
Svanborg, Catharina
Funding for this research was provided by:
Cancerfonden
Vetenskapsrådet
Kungliga Fysiografiska Sällskapet i Lund
Horizon 2020 Framework Programme (954360, 954360, 954360, 954360, 954360, 954360, 954360, 954360, 954360, 954360, 954360)
Lund University
Article History
Received: 7 November 2023
Accepted: 7 February 2024
First Online: 15 February 2024
Competing interests
: CS, TTH, MLYW and IA hold shares in HAMLET BioPharma, as a representative of scientists. CS, TTH, MLWY, IA, MG, AC and SA own shares in Linnane Pharma, which is developing the BAMLET project. Patents, with the scientists as inventors, have been filed to protect the therapeutic use of BAMLET. The other authors declare no competing interests.